The rising prevalence of chronic diseases and increasing life expectancy globally are major factors contributing to the growth of the Dry Age-Related Macular Degeneration Market. As the elderly population grows, so does the incidence of dry AMD, which remains the leading cause of vision loss among older adults. This demographic trend has prompted healthcare providers and pharmaceutical companies to focus heavily on developing innovative treatment options aimed at delaying disease progression and improving patient quality of life.
In addition to traditional therapies, research into regenerative medicine and stem cell treatments shows promise in the management of dry AMD. These novel approaches aim to repair or replace damaged retinal cells, potentially restoring vision in affected individuals. As such technologies mature and gain regulatory approvals, they are expected to be major growth drivers in the Dry Age-Related Macular Degeneration Market, offering new hope for patients and expanding treatment options available to ophthalmologists worldwide.